Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.84 |
| ▸ | BRD2 | P25440 | 1/20 | 0.84 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.84 |
| ▸ | TSPO | P30536 | 1/20 | 0.84 |
| ▸ | EP300 | Q09472 | 1/20 | 0.84 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.84 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mivebresib SCHEMBL29430453 | 0.91 | BRD4 (1.00) | BRD4BRD2ADORA2BTSPOEP300 | |
| Mivebresib SCHEMBL15068241 | 0.91 | BRD4 (1.00) | BRD4BRD2ADORA2BTSPOEP300 | |
| Mivebresib SCHEMBL29362711 | 0.91 | BRD4 (1.00) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL15069580 | 0.90 | BRD4 (1.00) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL29745735 | 0.90 | BRD4 (1.00) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL15069573 | 0.89 | BRD4 (1.00) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL15069791 | 0.89 | BRD4 (0.89) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL15069269 | 0.88 | BRD4 (1.00) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL15069631 | 0.87 | BRD4 (1.00) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL15069207 | 0.86 | BRD4 (1.00) | BRD4BRD2ADORA2BTSPOEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109384785-B | Pyrrolopyridinone derivatives, preparation method and medical application thereof | 浙江海正药业股份有限公司 | 2021-09-28 | — | — | CN | disclosed |